BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.

9 days ago

Clinical • Retrospective data • Review • Journal

BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)

BRAF V600E • BRAF V600 • BRAF wild-type

Erbitux (cetuximab) • Braftovi (encorafenib)

15d

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)

P1/2, N=38, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

15 days ago

Trial completion date • Trial primary completion date

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600

Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib)

16d

CA209-73R: Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer (clinicaltrials.gov)

P2, N=24, Active, not recruiting, Providence Health & Services | Trial completion date: Oct 2027 --> Jan 2027 | Trial primary completion date: Oct 2025 --> Jan 2026

16 days ago

Trial completion date • Trial primary completion date

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600

Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib)

17d

PHAROS: An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=98, Completed, Pfizer | Active, not recruiting --> Completed

17 days ago

Trial completion

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600

Mektovi (binimetinib) • Braftovi (encorafenib)

18d

Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib (clinicaltrials.gov)

P2, N=34, Not yet recruiting, Jinling Hospital, China

18 days ago

New P2 trial • Checkpoint inhibition

Zepsun (donafenib)

29d

Development and validation of a quick and sensitive UPLC-MS/MS method for measuring ensartinib in HLMs: investigation of structural alerts associated with metabolic lability and in silico toxicity. (PubMed, Analyst)

EST and Encorafenib (ECB as the internal standard) were differentiated using an isocratic mobile phase system on a reversed stationary phase (Eclipse Plus C18) column. In silico data proposed that minor structural modifications to the dichlorophenyl moiety or the piperazine ring during drug design may enhance the safety profile and metabolic stability relative to the properties of EST. Evaluating the EST metabolic stability and in silico ADME characteristics is essential for advancing innovative therapeutic research focused on improving metabolic stability.

29 days ago

Journal

ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • AXL (AXL Receptor Tyrosine Kinase)

ALK positive

Braftovi (encorafenib) • Ensacove (ensartinib)

30d

Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine. (PubMed, Future Oncol)

Notably, the recent US Food and Drug Administration approval of the avutometinib/defactinib combination for KRAS-mutated recurrent LGSOC marks a significant milestone in targeted therapy for this disease. Despite these advances, challenges remain in optimizing sequencing strategies and overcoming acquired resistance. This review addresses the importance of understanding the distinct pathophysiology of LGSOC, diagnostic challenges, limitations of conventional treatments, and evolving therapeutic approaches in LGSOC.

30 days ago

Review • Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation

Avmapki (avutometinib) • Fakzynja (defactinib)

30d

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov)

P1/2, N=53, Recruiting, University of Chicago | Suspended --> Recruiting

30 days ago

Enrollment open

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)

KRAS mutation • MSI-H/dMMR

Erbitux (cetuximab) • Avmapki (avutometinib)

Ophthalmic Toxicities in BEACON Triplet Therapy for BRAF V600E-Mutant Colorectal Cancer: A Case Series. (PubMed, J Anus Rectum Colon)

The BEACON regimen, comprising cetuximab, encorafenib, and binimetinib, is a critical treatment for BRAF-mutant metastatic colorectal cancer (mCRC). These cases highlight the importance of early recognition and proactive management of ocular toxicity in patients receiving BEACON therapy. Regular ophthalmological monitoring and appropriate dose adjustments are essential to prevent visual damage while maintaining treatment efficacy.

1 month ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF mutation • BRAF V600

Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)

Phase II Study Evaluating the Combination of Linperlisib, Azacitidine, and Liposomal Mitoxantrone in Treatment-Naïve Nodal TFH Cell Lymphoma (ChiCTR2500107944)

P2, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

1 month ago

New P2 trial

azacitidine • Zepsun (donafenib) • Itari (linperlisib) • Duoenda (mitoxantrone liposomal)

A randomized controlled clinical study on the efficacy and safety of combination/non combination of Donafenib and PD-1 monoclonal antibody with hepatic arterial infusion chemotherapy as first-line treatment for non-surgical hepatocellular carcinoma (ChiCTR2500109530)

P=N/A, N=78, Recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital

1 month ago

New trial

Zepsun (donafenib)